A subgroup analysis of the phase III trials of Provenge (Sipuleucel-T) suggests that there might be a dramatic role for Provenge in African-American men who have advanced prostate cancer that has become castration-resistant (mCRPC). The analysis, which was released at the American Urological Association 2012 Annual Scientific Meeting, was headed up by Colonel David G. [...]
At a recent meeting that I attended it was reported by a nurse that one of her patients with advanced prostate cancer with only a PSA recurrence and lymph node involvement on a scan was rejected by their insurance company for reimbursement for Provenge. The insurance company indicated that to pay for the treatment they [...]
There has been an on-going debate on the advanced prostate cancer on-line support group about the issue of the efficacy of Provenge in light of the expectation of a person's increasing PSA number while getting the treatment. For many men with advanced prostate cancer this is a reason they elect to pass on this treatment [...]
I have heard some occasional discussion that once (that is if) enzalutamide (MDV-3100) is approved by the FDA for the treatment of men with advanced prostate cancer, it will over shadow Provenge. On the contrary, I believe that the approval of enzalutamide will actually encourage additional use of Provenge resulting in the increasing use of [...]
The recent AUA meetings in Atlanta had a number of interesting abstracts presented that concern men with advanced prostate cancer. Some of the more interesting abstracts were look back analysis of sipuleucel-T (Provenge) done by consultants for Dendreon, the company who manufactures Provenge. They took the data from the al three of the phase III [...]